Journal of Oncology Pharmacy Practice

Article	Citations
Assessing the impact of aprepitant on response to dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP)	43
Comprehensive pharmacological geriatric assessment compared to usual care in an older adult with cancer in the absence of polypharmacy	19
Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients	16
Mercaptopurine induced myelosuppression in a child with a NUDT15 rs116855232 homozygous variant	15
Hydroxyurea- a cost effective treatment in developing countries for Atypical Chronic Myeloid Leukemia (aCML): Case Report of Two Patients	15
The physical exam’s role in determining dose-limiting toxicity prior to immunochemotherapy administration in lymphoma	14
Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbidities	14
Corrigendum to A review on radiation induced nausea and vomiting: “Current management strategies and prominence of radio sensitizers”	14
Immunosuppressant adherence in adult outpatient hematopoietic cell transplant recipients	14
Pharmacists’ practices and views regarding management of sexual health in patients with cancer	14
Rituximab-induced severe acute thrombocytopenia in a patient with splenic marginal zone lymphoma	13
A room of errors simulation to improve pharmacy operators’ knowledge of cytotoxic drug production	13
Trend analysis of pharmacist involvement in cancer care in Japan from 2015 to 2020: A nationwide survey study on hospital pharmacy practice	12
Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies	12
Evaluation of hepatotoxicity due to conditioning regimens in beta thalassemia major and aplastic anemia patients undergoing bone marrow transplantation	11
Initial real-world experience with ribociclib in advanced breast cancer	11
Identifying health disparities in lenalidomide access	11
Clinical characteristics and risk factors for oxaliplatin hypersensitivity reactions in patients with colorectal cancer	10
Safety and efficacy of Vitamin C, Vitamin E, and selenium supplementation in the oncology setting: A systematic review	10
Exploring the potential relationship between antineoplastic agents and their association with stomatitis and oral candidiasis in cancer patients	10
Nivolumab-induced immune-related neutropenia in a renal cell carcinoma patient	10
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer	10
Cellular therapy site-preparedness: Inpatient pharmacy implementation at a large academic medical center	10
Post COVID availability of oncology drugs – Is this the new normal on both sides of the Atlantic?	10
Polypharmacy and drug-drug interactions in metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors	10

Pneumonitis associated with Trastuzumab emtansine in a patient with metastatic breast cancer	9
Evaluation of proteinuria monitoring practice patterns and treatment implications in patients with cancer receiving bevacizumab products	9
Premedication strategy in cetuximab rechallenge after Grade 2 hypersensitivity reactions	9
Acute pancreatitis associated with pembrolizumab-induced hypertriglyceridemia	9
Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 124 centers	9
CAPhO Conference 2024 Abstract Book	9
Assessment of chemical contamination by cancer drugs during use of the RIVA TM compounding robot: A pilot study	8
Revitalizing oncology medications access in Saudi Arabia: Current challenges and recommendations by the Saudi Oncology Pharmacy Assembly	8
Evaluating aggressiveness of end-of-life care in patients with advanced cancer: A retrospective single-center analysis	8
Efficacy and safety of bone management agents administered at 12 weeks vs. 4 weeks in patients with bone metastases: A systematic review	8
Hypokalemia, hypomagnesemia, and hyponatremia are associated with acute kidney injury in patients treated with cisplatin	8
Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis	8
Estimation of financial burden of breast cancer and its effect on quality of life	8
Gemcitabine-associated DRESS syndrome: A case report	8
Melphalan on day -1 versus day -2 in patients with plasma cell disorders undergoing autologous stem cell transplant	8
Incorporation of novel therapies for the management of sickle cell disease: A pharmacist's perspective	8
One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant	8
Use of long-term corticosteroids in patients treated with CAR T-cell therapy	8
Risk assessment of pneumatic tube systems for in-hospital transportation of biotherapeutics	7
Use of two general-purpose scales to assess clinical pharmacy activities in a cell transplantation unit	7
Continuous versus intermittent tacrolimus for graft-versus-host disease prophylaxis in pediatric hematopoietic stem cell transplantation patients (Tic Tac)	7
Clinical uses and safety concerns of tyrosine kinase inhibitors with a focus on novel drugs: A narrative review	7
Nivolumab–ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment	7
Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev®), a bevacizumab biosimilar, under extended in-use conditions	7
Risk-based analytical quality control of chemotherapy preparations: A simulation and FMECA approach	7
Medical marijuana in the treatment of cancer-associated symptoms	7
Pure red cell aplasia occurring during ibrutinib therapy for chronic lymphocytic leukemia	7
Pembrolizumab related perforated appendicitis	7
Hepatic sinusoidal congestion associated with inotuzumab therapy in patients with B-cell acute lymphoblastic leukemia, a proposal for a new clinical entity: Calicheamicin syndrome	7
Attitude of healthcare professionals toward the use of complementary and alternative medication during anti-cancer therapy	7
Evaluation of voriconazole related adverse events in pediatric patients with hematological malignancies	7
Impact of institutional interventions on the rate of paclitaxel hypersensitivity reactions	7
Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer	7
Perception, knowledge, and handling practice regarding the risk of exposure to antineoplastic drugs in oncology day hospitalization units and compounding unit staff	7
The inpatient oncology pharmacist experience in the era of temporary oncologists	7
QTc prolongation during levofloxacin and triazole combination chemoprophylaxis: Prevalence and predisposing risk factors in a cohort of hematopoietic cell transplantation recipients	7
Oral oncolytic monitoring pilot with patient-reported outcomes and adherence assessments	7
Capecitabine-related neurotoxicity presenting with agraphia	7
Assessment of adverse events among cervical cancer patients at Kenyatta National Hospital	7
Expanding oncology pharmacist teams: Justifying the return on investment	7
Papilledema and idiopathic intracranial hypertension due to the possible potentiation of ATRA by posaconazole in a case of acute promyelocytic leukemia	7
Prevalence and risk factors of trastuzumab induced cardiotoxicity in Tunisian HER2-positive breast cancer patients	7
Retrospective cross-sectional study of drug utilisation and expenditure of anticancer drugs at zonal referral hospital central, Tanzania	7
Belantamab mafodotin for relapsed or refractory multiple myeloma	7
Intravenous route for folate supplementation in a patient with celiac disease treated by pemetrexed-based chemotherapy for non-small-cell lung cancer	7
Carfilzomib-induced thrombotic microangiopathy. A case report	7
Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies	6
Predictors of fluid overload in allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide	6
Pembrolizumab induced type 1 diabetes mellitus in a patient with metastatic melanoma and literature review on steroids as a treatment option	6
Evaluation of potential drug-drug interactions in cancer patients at a tertiary care hospital in Pakistan	6

Safety and tolerability of lenalidomide maintenance dosing in patients with multiple myeloma post-autologous stem cell transplant	6
Antimicrobial prophylaxis in pediatric patients with leukemia: Reducing incidence of febrile neutropenia episodes and bloodborne infections	6
Inpatient utilization of immune checkpoint inhibitors and clinical outcomes	6
Chemotherapy-induced neutropenia among breast Cancer patients in a tertiary care hospital: Risk and consequences	6
Erratum to Evaluation of antibiotic appropriateness at an outpatient oncology centre	6
Pharmacist's role in the management of drug–drug interactions caused by nirmatrelvir/ritonavir in COVID-19 oncohematology patients	6
Usefulness of hydrocortisone prophylaxis for oxaliplatin-induced hypersensitivity reactions: A retrospective study	6
Innovation in hospital pharmacy: Modeling the installation of automated dispensing systems based on an oncology hospital experience transfer	6
Preservation of cognitive function after brain irradiation	6
Hyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma	6
Safety and tolerability of adjuvant combination treatments following KEYNOTE-522 for early-stage or locally advanced breast cancer with residual disease	6
Successful dasatinib therapy in newly diagnosed chronic myeloid leukemia in the setting of short bowel syndrome	6
Oral anticancer medicine interventions: A cross-sectional study in French community pharmacies	6
Retrospective study on the efficacy and tolerability of dose modification of PD-1 and PD-L1 inhibitors in hospital-system community outpatient cancer clinics	6
Acute infusion-related reactions in pediatric patients receiving etoposide at a tertiary cancer center	6
Rasburicase induced methemoglobinemia: A systematic review of descriptive studies	6
Investigating effective methods of clinical pharmacy training on oncology for community pharmacists: An observational study	6
ISOPP Standards for the Safe Handling of Cytotoxics	6
Evaluation of oral silymarin formulation efficacy in prevention of doxorubicin induced hepatotoxicity in patients with non-metastatic breast cancer	6
Rapid drug desensitization to taxanes: a descriptive study from Turkey	6
Evaluation of potential cost savings through chemotherapy and biotherapy dose-rounding at a pediatric institution	6
Genetic variants found in paediatric oncology patients with severe chemotherapy-induced toxicity: A case series	6
Hypersensitivity reaction to Abiraterone, successful desensitization protocol in prostate cancer patient	6
Examining clinical pharmacist interventions and identifying opioid medication-related issues in patients with cancer	5
The association between patient satisfaction with information and adherence to oral anticancer agents	5
Oncology pharmacy practice in Nepal: Integration, challenges, and policy directions	5
Myocarditis and diaphragmatic rhabdomyolysis with respiratory failure in a patient with metastatic melanoma treated with Nivolumab	5
Adverse drug reactions associated with doxorubicin and epirubicin: A descriptive analysis from VigiBase	5
Immune checkpoint inhibition in advanced colorectal cancer with inherited and acquired microsatellite instability: Current state and future directions	5
Feasibility study of an innovative simulation-based learning program in hospital oncology pharmacy: A pilot project in a faculty of pharmacy	5
An assessment of the prevalence of drug therapy problems and its associated factors among ovarian cancer patients at Kenyatta National Hospital	5
Comparison of first and third generation EGFR-TKIs for the treatment of advanced non-small cell lung cancer: A real-world study	5
A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review	5
Cancer procoagulant inhibitors: New drugs for an old target	5
Characteristics of the clinical pharmacist interventions at the National Center for Cancer Care and Research Hospital in Qatar	5
Interstitial pneumonitis associated with leuprorelin acetate for a prostate cancer: A case report	5
Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma	5
Anti-cancer drug waste disposal practices and wastewater management in hospitals: A Lebanese survey	5
Reversible Cardiomyopathy after Rituximab Treatment in a Chronic Lymphocytic Leukemia Patient	5
Bevacizumab-induced isolated oculomotor nerve palsy in glioblastoma multiforme	5
Effectiveness of antiemetic in reducing chemotherapy-induced nausea and vomiting in adult patients; An oncology center experience	5
Panitumumab Associated Acute Pancreatitis	5
Poor tolerability of lenvatinib in elderly patients ≥80 years old with hepatocellular carcinoma: A multicenter observational study	5
Descriptive analysis of the efficacity of R-GEMOX /R-IE/R-CEPP in patients with relapsed/refractory (R/R) transplant-ineligible diffuse large B-cell lymphoma (DLBCL)	5
Comment on ‘risk factors associated with nausea and vomiting in children with cancer receiving chemotherapy’	5
Safety of alisertib in the treatment of solid and hematological cancers: A systematic review and meta-analysis of randomized controlled trials	5
Rasburicase dose optimization for tumor lysis syndrome management in a network of community oncology practices	5
Retrospective drug utilization review of meropenem and role of infectious disease pharmacist in specialized cancer care hospital	5
Therapeutic outcomes of patients with acute erythroid leukemia treated with hypomethylating agents	5
Evaluation of awareness about importance of high fever in leukemia and lymphoma patients receiving chemotherapy among healthcare professionals working in pharmacies other than hospital pharmacies: A s	4
Knowledge, attitudes, and practices among oncology pharmacists on cytotoxic drug reconstitution in Sri Lanka: A cross-sectional study	4
A prospective analysis of efficacy of dexamethasone-sparing antiemetic regimens in high and moderate emetogenic chemotherapy	4
A case of palmar-plantar erythrodysesthesia in a lung cancer patient receiving atezolizumab maintenance	4
Late side effects of cancer treatment in childhood cancer survivors	4
Cytotoxic surface contamination in hospitals: Current practices, challenges and perspectives	4
Posterior reversible encephalopathy syndrome triggered by FLOT (5-fluorouracil, oxaliplatin, docetaxel, and calcium levofolinate) chemotherapy and thrombocytopenia (docetaxel and cisplatin) chemothera	4
Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 122 centers	4
Misalignment between patient preferences and clinician expectations: Do press releases make clinicians impatient to the detriment of patients?	4
Cost savings and cost avoidance with the inpatient clinical pharmacist interventions in a tertiary cancer care hospital	4
Evaluating patients on immune checkpoint inhibitors for cardiac adverse events: The EPICC study	4
Exploring the toxicity and clinical outcomes of doxorubicin, cyclophosphamide, and taxane-based chemotherapies in women with breast cancer in Bangladesh	4
Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort	4
Brigatinib is a cost-effective treatment in first-line anaplastic lymphoma kinase mutation-positive (ALK + ) advanced non-small cell lung cancer (NSCLC) with brain metastases	4
Acquired Hemophilia A following Pfizer-BioNTech SARS CoV-2 mRNA vaccine, successfully treated with prednisolone and rituximab	4
Gefitinib induced Pemphigus Vulgaris with PRIDE complex	4
Patterns and predictors of antidepressant prescribing among adults with cancer and depression in ambulatory care settings in the United States	4
Imatinib mesylate-induced acute hepatotoxicity	4
Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation	4
Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer	4
Carboplatin dosing in obese patients	4
Cabozantinib-induced heart failure	4
Laryngopharyngeal dysesthesia as a possible clinical manifestation of a cytokine release reaction due to oxaliplatin	4
Medication errors in an oncology inpatient setting in India—Audit by clinical pharmacists	4
The role of the pharmacist in the hospital discharge of cancer patients: an integrative review	4
Residual contamination in antineoplastic drug packaging	4
Perceptions and prevalence of marijuana use among cancer patients managed at an outpatient department in Zimbabwe: A brief report	4
Meperidine compared to morphine for rigors associated with monoclonal antibody-related infusion reactions	4
Investigation of the frequency of bortezomib neuropathy in patients with multiple myeloma diagnosis with normal and abnormal genetic characteristics	4
Manual versus automated chemotherapy preparation: A retrospective pharmaco-economic analysis	4
Real-world experience of abemaciclib for adjuvant and metastatic breast cancer	4

The effect of examining somatic alterations with NGS in patients with solid tumors, on patient management: A single-center experience in Turkey	4
Pro-BNP in the differential diagnosis of dyspnea in patients treated with immune-checkpoint inhibitors: Case Report	4
Drug induced lupus associated with Trastuzumab emtansine in a patient with metastatic breast cancer	4
Implementation of pharmaceutical care service to elderly cancer patients in a tertiary care hospital in South India	4
Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: An integrative review	4
Evaluation of real-world versus clinical trial outcomes of tyrosine kinase inhibitor therapy for chronic myeloid leukemia	4
Hypersensitivity reactions to chemotherapy and biologics: Outcomes and safety of 927 desensitization in Mexico	4
Bilateral epithelial keratopathy and punctate keratitis due to ribociclib	4
Single center evaluation on the use of conditionally ordered low molecular weight heparins in malignant hematology patients with venous thromboembolism	4
Automated chemotherapy compounding: Process optimization for the preparation of admixture containing high-dose of cyclophosphamide	4
Central line-associated Rhizobium radiobacter bloodstream infection in two allogeneic hematopoietic cell transplant recipients	4
Safety and oncological effectiveness after desensitization in patients with previous hypersensitivity reactions to chemotherapy	4
Safe handling of hazardous drugs	4
Acute pancreatitis secondary to tamoxifen-associated hypertriglyceridemia: A clinical update	4
Oncology stewardship: A narrative review of principles and practices	4
Pembrolizumab for advanced non-small cell lung cancer (NSCLC): Impact of autoimmune comorbidity and outcomes following treatment completion	4
Pharmacy practitioners’ adherence to safe-handling practices of chemotherapeutic drugs: A cross-sectional study in Saudi Arabia	4
Pro-adherence complementary audiovisual educational intervention model for chronic myeloid leukemia patients treated with imatinib mesylate	4
Skin toxicity after Filgrastim treatment for an Ewing's sarcoma patient	4
Successful Treatment of a 92-Year-Old Classic Kaposi's Sarcoma Man With Ultra-Low Dose Oral Etoposide	4
Factors associated with potentially inappropriate medications in elderly with multiple myeloma	4
Managing suspected myasthenia gravis and myositis induced by pembrolizumab in a Jehovah's Witness sarcoma patient	4
Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma	3
An assessment of exposed syringe inner walls as a route of exposure from hazardous drugs	3
Corrigendum to Role of sacituzumab govitecan in solid tumors	3
Cytomegalovirus viremia and hepatitis B reactivation in patient with RET fusion-positive non-small cell lung cancer treated with pralsetinib	3
Evaluating the clinical benefit of pembrolizumab as a first-line agent in advanced solid tumors: A comprehensive review	3
Role of clinical pharmacist in the palliative care of adults and elderly patients with cancer: A scoping review	3
Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia	3
Hypercalcemia associated with interaction between all trans retinoic acid and fluconazole in an acute promyelocytic leukemia and acquired hypoparathyroidism case	3
Antithrombotic and hemostatic stewardship: Evaluation of romiplostim for treatment of thrombocytopenia at a large academic medical center	3
A critical appraisal of South African oncology pharmacy standards: A comparison with international best practice standards	3
Pulmonary embolism and bradycardia in a NSCLC patient treated with crizotinib for a rare mutation	3
Toxic hepatitis in metastatic breast cancer patient using ribociclib and denosumab	3
Nearly complete hair re-pigmentation in an older patient treated with hydroxyurea for essential thrombocytosis	3
Acquired angioedema late in the course of nivolumab treatment	3
Development of an African paediatric oncology pharmacy curriculum: A SIOP Africa 2024 pharmacy workshop output	3
Nutrition support pharmacy practices in hospitalized cancer patients admitted to bone marrow transplant units: A 3-year retrospective analysis of clinical nutrition support pharmacists’ interventions	3
Pharmacist interventions in optimising opioid medication therapy in pain management for palliative care patients: A systematic review	3
Concordance analysis of two databases to search for potential drug interactions in onco-hematologic patients	3
Chronic cannabis use in breast cancer survivors: A questionnaire study of Israeli patients	3
Evaluating the efficacy of a premedication regimen including high-dose cetirizine in reduction of hypersensitivity reactions to paclitaxel: A retrospective cohort study	3
Implementation of a comprehensive medication management service for radioiodine therapy patients at an oncology hospital in Rio de Janeiro	3
Factors affecting medication adherence in patients using oral chemotherapy: A descriptive study	3
Rechallenges without desensitization following platinum-based chemotherapy reactions	3
Impact of low- and high-risk operators handling irinotecan on the blood contamination of health care workers in oncology day care units	3
New-onset persistent hyperglycemia with initiation of brentuximab treatment	3
Midostaurin-Associated acute pancreatitis	3
Herpesviral encephalitis associated with bortezomib use in a patient with multiple myeloma and associated light-chain amyloidosis	3
Subacute cutaneous lupus erythematosus following ribociclib therapy for metastatic breast cancer	3
Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma	3
A study to quantify knowledge obtained during the British Oncology Pharmacy Association (BOPA) Introduction to Oncology (ITO) Course	3
A multicentre study with real-world data of the use of palbociclib in the treatment of breast cancer: Treatment duration correlates with dose reductions	3
Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma	3
Perception, knowledge, practices and training regarding the risk of exposure to antineoplastic drugs in three French compounding units	3
Artificial intelligence-based muscle analysis risk assessment of treatment-related toxicity in metastatic colorectal cancer	3
Thrombotic Thrombocytopenic Purpura associated with Pembrolizumab	3
Interpersonal communication-, education- and counselling-based interventions to support adherence to oral anticancer therapy: a systematic review	3
Assessment of adverse drug reactions among acute myeloid leukaemia patients at Kenyatta National Hospital	3
Nivolumab-induced pneumonitis and cardiopathy in a patient with relapsed Hodgkin's lymphoma	3
Real world comparison of filgrastim to filgrastim-sndz in patients with chemotherapy-induced neutropenia	3
Predictive risk factors associated with cancer therapy-related cardiac dysfunction: A retrospective cohort study	3
A real-world multicentre evaluation of atezolizumab plus platinum-etoposide chemotherapy as first-line treatment in patients with extensive-stage small cell lung cancer in Italy	3
The effect of Bevacizumab treatment on the incidence of hypertension in patients with ovarian cancer: a systematic review and meta-analysis	3
Drug extravasation with Enfortumab vedotin	3
Corrigendum to Audit on Oral Systemic Anti-Cancer Therapies (SACT) Adherence Using the Morisky Medication Adherence Scale (MMAS): Implications for Pharmacy Counselling	3
Oncology stewardship practice in the United States: A Hematology/Oncology Pharmacy Association national survey	3
Effect of direct oral anticoagulants compared to enoxaparin on objective response to immune checkpoint inhibitors in patients with lung cancer	3
Risk assessment of personnel exposure in a central cytotoxic preparation unit using the FMECA method	3
Cytogenetic guided therapy using blinatumomab and inotuzumab ozogamicin in a patient with relapse/refractory acute lymphoblastic leukemia	3
Overcoming language barriers to enhance pharmaceutical care: Design and validation of a pictogram-based tool for cancer patients	3
Optimizing antimicrobial prophylaxis strategies in acute leukemia patients: Assessing the efficacy of fluconazole	3
Redispensing of expensive oral anticancer medicines: A practical application	3
Safety outcomes of teclistamab accelerated dose escalation	3
Optimizing intermittent dosing of oral small molecule inhibitors	3
Evaluating the impact of a pharmacist-led venetoclax ramp-up clinic for chronic lymphocytic leukemia patients: A retrospective chart review	3
Assessment of potential drug–drug interactions in hospitalized cancer patients	3
Mild forms of thrombotic microangiopathy in patients with advanced pancreatic cancer receiving gemcitabine and nab-paclitaxel	3
A comprehensive study of adverse effects of chemotherapy on female breast cancer patients in NORI Cancer Hospital, Islamabad in a developing country	3
Implementation of Partnered Pharmacist Medication Charting in haematology and oncology inpatients	3
Necrotizing leg gangrene from invasive cutaneous Kaposi sarcoma, reversed by pegylated liposomal doxorubicin	3
A pilot study to determine the feasibility and safety of pharmacist and nurse driven management of venetoclax ramp-up in patients with chronic lymphocytic leukemia	3
Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma	3
A pilot study about methods to reduce prescription errors in a chemotherapy day unit – Aspects to consider in pharmacist verification process	3
Vinorelbine-related tetraplegia due to severe peripheral neuropathy	3
Diagnosis and management of immune checkpoint inhibitor-associated adrenal insufficiency: A single-institution experience	3
Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis	3
A simple and inexpensive method to monitor and minimize exposure from manipulation of cytotoxic drugs	3
Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoring	3
Therapeutic potential of phytoconstituents in oncocosmetics: A systematic review on radiodermatitis management	3
A case of castration-resistant metastatic prostate cancer who continued treatment with enzalutamide after epileptic seizure	3
Advancements in the use of nanopharmaceuticals for cancer treatment	3
The relationship between immune-related adverse events during ipilimumab monotherapy and survival outcomes among melanoma patients: A systematic review	3
Workflow evaluation of environmental contamination with hazardous drugs during compounding and administration in an UK hospital	3
Role of Ketamine and Opioid Rotation in the Management of Opioid Induced Hyperalgesia in a Patient With Acute Promyelocytic Leukemia	3